JNJ-89495120

JNJ-89495120 is a Janssen small-molecule investigational drug in Phase 2 for recurrent major depressive disorder. The trial's primary endpoint, change in MADRS score from baseline to Day 5, signals Janssen is hunting for rapid-acting antidepressant activity, not the four-to-six-week onset typical of SSRIs [1]. With n=107 enrolled and recruitment closed, the Phase 2 readout is the near-term catalyst. The competitive bar has risen: Spravato (esketamine, J&J's own intranasal NMDA antagonist) hit roughly $1.0 billion in 2024 sales [5], and Auvelity (dextromethorphan-bupropion, Axsome) reached the market in August 2022 as the first oral antidepressant with a one-week onset claim [6]. JNJ-89495120 must beat both, ideally as a convenient oral, to matter commercially [3].

Phase 2, single trial (NCT06785012), ACTIVE_NOT_RECRUITING per ClinicalTrials.gov, which means the 107 enrolled patients have been dosed and the trial is in follow-up or analysis [1]. No publicly disclosed FDA designations: no breakthrough therapy, no fast track, no RMAT, no orphan status. That is not unusual for a depression program at Phase 2. Breakthrough designations usually arrive after a positive Phase 2 readout, not before. The compound is novel. It has an RxNorm CUI (2179496) assigned by the NLM, which means it has been registered as a distinct investigational entity but confers no regulatory advantage. It is not approved anywhere in the world for any indication. Janssen has not disclosed a public timeline for the readout. The APA Annual Meeting (May 2026) passed without a disclosed readout. Next likely catalyst windows are ECNP (September/October 2026), J&J Q3 2026 earnings (expected October 2026), and ACNP (December 2026). J&J typically pre-announces positive psychiatry readouts at quarterly earnings before peer-reviewed disclosure [5].

Mechanism is not publicly disclosed. Janssen has filed the molecule under code-name only and has not released a target, modality, or animal-model package. That is unusual for a Phase 2 program at a top-15 pharma and limits external assessment. What can be inferred from the trial design is that Janssen is targeting rapid antidepressant onset. The Day 5 primary endpoint matters because SSRIs and SNRIs (the standard of care for depression) take four to six weeks to show effect. Two products have broken that timeline: Spravato (esketamine), Janssen's own NMDA receptor antagonist delivered intranasally under a REMS program [3], and Auvelity (dextromethorphan-bupropion), an oral combination acting on NMDA and sigma-1 receptors, FDA-approved in August 2022 with a one-week onset claim from its key GEMINI trial [6]. NMDA receptors sit on neurons and normally let glutamate signal through. Blocking or modulating them appears to rapidly rewire mood circuitry in depressed patients, though the exact biology is still debated. JNJ-89495120 could hit NMDA differently from esketamine and dextromethorphan, or it could work through another fast-onset mechanism. Sigma-1 modulation, muscarinic receptor activation (the path KarXT took to FDA approval for schizophrenia), and biased mu-opioid agonism have all produced fast-onset antidepressant signals in academic and small-biotech work. Without disclosure, this is pattern-matching, not evidence. The validation question is binary: either Day 5 MADRS shows a clinically meaningful separation from placebo, or it does not. Mechanism only matters if the effect is real, at which point Janssen will likely disclose target identity for competitive positioning.

NCT06785012 is a Phase 2 single-trial program sponsored by Janssen Research & Development [1]. Enrollment target was 107 patients with recurrent major depressive disorder. Per the CT.gov eligibility criteria, participants must have a primary diagnosis of recurrent MDD (at least one prior episode), be in a current episode lasting 2-24 months, and may have tried up to two prior treatments for the current episode [1]. This is not strict treatment-resistant depression (which typically requires 2+ failed adequate trials), but it does enrich for patients with some prior treatment exposure. The population sits between broad first-line MDD and the TRD population Spravato is approved in. Status is ACTIVE_NOT_RECRUITING. The primary endpoint is change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Day 5. MADRS is a clinician-rated 10-item scale that scores 0 to 60. Drugs that move it three to four points more than placebo are typically considered clinically meaningful in MDD. The Day 5 endpoint is the signal in the design. Standard MDD trials use Week 6 or Week 8 endpoints. Ketamine and esketamine trials use 24-hour, Day 2, and Day 7 windows. Picking Day 5 commits the program to a rapid-onset hypothesis. If the drug works on a slower SSRI-like timeline, the trial will miss. The comparator is not explicitly itemized in the public CT.gov record beyond the trial design summary, but Phase 2 MDD trials of this size and design are uniformly randomized placebo-controlled, and the structured record is consistent with that. A 107-patient trial gives modest statistical power; it is sized to detect a meaningful effect, not to be a registration-grade study. A positive readout would trigger a larger Phase 3 program. Design concern: depression trials famously have large placebo response rates, often 30 to 40 percent on the response criterion. A 107-patient trial with a 5-day window leaves limited room to absorb placebo noise. Janssen knows this from Spravato development.

Our model estimates a 6% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant concern. Depression trials have placebo response rates of 30 to 40 percent, which destroys statistical power. Janssen designed around this by picking a Day 5 endpoint where placebo response typically has not fully built up. If placebo response runs hot, the trial misses. If the drug works on an SSRI-like timeline (four to six weeks), the trial also misses because Day 5 is too early. The endpoint is a calculated bet on rapid onset. Safety risk is elevated by mechanism opacity. Spravato has REMS requirements because esketamine produces dissociation and has abuse potential [3]. Any NMDA-acting drug inherits some version of that risk profile. Auvelity's dextromethorphan component is also an NMDA antagonist and a sigma-1 agonist; its label avoided REMS but did require attention to drug-drug interaction risk through CYP2D6 [6]. If JNJ-89495120 hits a similar fast-onset receptor system, expect comparable safety questions. Janssen's CNS safety packaging is strong, but FDA has become more cautious post-Spravato about psychedelic-adjacent and dissociative mechanisms. Execution risk is low. Janssen Research runs psychiatry trials competently and has a CNS development infrastructure that includes Spravato post-marketing data. Enrollment is complete, which removes that variable. Commercial risk is real even if the trial succeeds. The MDD market is large but pharmacoeconomically punishing. Generic SSRIs cost pennies. Spravato reached roughly $1.0 billion in 2024 sales [5] despite REMS restrictions, in-clinic administration requirements, and payer pushback; J&J has guided to continued growth. Auvelity, as the only approved oral with a rapid-onset claim, is the more direct commercial template for an oral JNJ-89495120. IV ketamine clinics (compounded, off-label) also remain de facto competition in the rapid-onset category. Any oral, fast-acting antidepressant that needs no REMS could compete strongly, but a drug with administration restrictions or REMS will hit the Spravato ceiling. Janssen needs JNJ-89495120 to be both fast-acting and convenient to dispense, which is a hard combination.

Worth watching, with a specific catalyst. The Day 5 MADRS readout from NCT06785012 is a binary signal [1]. If Janssen reports a 3-point or greater placebo-adjusted reduction with a clean safety profile, this is a real drug and the Phase 3 program will be announced quickly. If the readout is flat or marginal, the program likely gets quietly deprioritized. APA Annual Meeting (May 2026) passed without a disclosed readout. The next catalyst windows are ECNP (September/October 2026), J&J's Q3 2026 earnings call (expected October 2026), and ACNP (December 2026). Quarterly J&J earnings are the most likely first disclosure venue for a positive result, because J&J typically pre-announces meaningful clinical wins [5]. The competitive frame matters. JNJ-89495120's most direct approved competitor is Auvelity, not Spravato. Spravato is intranasal under REMS and lives mostly in certified clinics; Auvelity is oral, REMS-free, and carries a one-week onset claim [6]. If JNJ-89495120 is oral, the bar is 'better than Auvelity on speed, durability, or tolerability.' If JNJ-89495120 ends up with REMS, the bar collapses back to a Spravato-like ceiling. For J&J the program is meaningful but not transformative. J&J's 2024 total revenue was $88.8 billion per its 2024 10-K, with new Medicine at $57.0 billion [4]. Spravato as the comparable rapid-acting antidepressant hit approximately $1.0 billion in 2024 [5]. Even a successful oral follow-on could add a few hundred million to a low single-digit billion in revenue at peak, which is incremental for J&J but a real franchise extension for a neuroscience portfolio that now also includes Caplyta (acquired via the Intra-Cellular Therapies deal closed in 2025) alongside Spravato and Invega. The signal here matters less for J&J's overall valuation and more for what it says about whether the rapid-acting antidepressant category has a second viable oral entry alongside Auvelity.